142:
In March 2024 Kimer Med announced it has signed a contract valued at up to USD$ 750,000 (NZD$ 1.3 million) with
Battelle Memorial Institute (Battelle), the world’s largest independent, nonprofit research and development organisation. The contract is focused on the discovery and development of new
133:
In June 2023 Kimer Med reported that it had "achieved two 100% positive results in tests against the priority viruses Dengue (DENV-2) and Zika (ZIKV). The tests were carried out by an independent laboratory in the United States, where Kimer Med’s antiviral compound, VTose, demonstrated 100%
105:
families. In total it was predicted that $ 500,000 per year for 4 years would be needed to optimise and demonstrate DRACOs against clinically relevant viruses, however, two crowdfunding campaigns for $ 90,000 both failed to reach their target in 2016.
148:
The same article reported that since it launched in 2020, "Kimer Med has since developed innovative antivirals that have shown efficacy against 11 different viruses, including Dengue (all four types), Zika virus, and Herpes
Simplex-2 (HSV-2)."
398:(5). State Key Laboratory of Biocontrol, Guangzhou Higher Education Mega Center, School of Life Sciences, Sun Yat-sen University, North Third Road, Guangzhou, 510006, Guangdong, People's Republic of China: 1239–47.
342:
203:
during transcription. Cell death is effected via one of the last steps in the apoptosis pathway in which complexes containing intracellular apoptosis signalling molecules simultaneously bind multiple
127:
was published. According to the study, DRACO was nontoxic in uninfected mammalian cells, and cells infected with H1N1 influenza virus showed a "significant", dose-dependent level of apoptosis.
85:
for further testing and development; "the team looks forward to larger scale animal trials and clinical human trials within a decade or less". Dr. Todd Rider presented at the
110:
725:
574:
207:. The procaspases transactivate via cleavage, activate additional caspases in the cascade, and cleave a variety of cellular proteins, thereby killing the cell.
144:
296:
318:
135:
390:
Guo C, Chen L, Mo D, Chen Y, Liu X (March 15, 2015). "DRACO inhibits porcine reproductive and respiratory syndrome virus replication in vitro".
47:
157:
There are very few therapies or prophylactics for serious viruses, but for the ones that do exist, they can be divided into 3 categories:
139:
The same article reported that Kimer Med’s antiviral VTose compounds have now shown efficacy against a total of seven different viruses.
720:
343:"Dr. Todd Rider from MIT Announces IndieGoGo Campaign to Raise Funds to Test and Optimize DRACOs Against Clinically Relevant Viruses"
447:
433:
134:
effectiveness against both Dengue and Zika virus in viral cytopathic effect (CPE) reduction assays, with low toxicity."
637:
538:
210:
It has been shown that DRACOs are nontoxic in 11 mammalian cells types and effective against 15 different viruses.
477:(Articles in Press). Applied Virology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
50:. In cell culture, DRACO was reported to have broad-spectrum efficacy against many infectious viruses, including
467:"Double-Stranded RNA Activated Caspase Oligomerizer (DRACO): Design, Subcloning, and Antiviral Investigation"
109:
In 2015, an independent research group reported to have successfully observed antiviral activity against the
130:
In August 2020 a company called Kimer Med in New
Zealand started developing VTose, a derivative of DRACO.
542:
20:
448:"This man's potentially huge medical breakthrough can't get funding, so he's trying something desperate"
427:
561:
Rider, T. H.; Zook, C. E.; Boettcher, T. L.; Wick, S. T.; Pancoast, J. S.; Zusman, B. D. (July 2011).
250:
120:
As of
December 2015, research related to DRACOs had ground to a halt due to a lack of funding.
187:. Differentiation between infected and healthy cells is made primarily via the length and type of
415:
690:
653:
598:
407:
278:
82:
588:
578:
478:
399:
268:
258:
703:
666:
621:
529:
86:
539:"MIT Lincoln Laboratory researchers develop a technique to cure a broad range of viruses"
123:
In July 2020, a paper from another independent research group about the effects of DRACO
254:
167:
Interferons, but they are less virus specific and are only receptive to certain viruses.
78:
selectively in virus-infected mammalian cells, while leaving uninfected cells unharmed.
593:
562:
465:
Sharti M, Esmaeili
Gouvarchin Ghaleh H, Dorostkar R, Jalali Kondori B (July 28, 2020).
273:
236:
184:
63:
43:
714:
98:
419:
161:
Special inhibitors of a virus-associated target (e.g. HIV protease inhibitors, RNAi)
90:
59:
51:
583:
263:
524:
466:
164:
Vaccines, but vaccines require modification for each new virus or viral strain.
611:
482:
403:
200:
102:
67:
55:
366:
89:'s SENS6 conference. He left the Draper Laboratory in May 2015 and started a
196:
94:
75:
602:
411:
282:
171:
So in order to overcome these obstacles the antiviral DRACO was developed.
191:
transcription helices present within the cell. Most viruses produce long
241:
235:
Rider TH, Zook CE, Boettcher TL, Wick ST, Pancoast JS, Zusman BD (2011).
38:
546:
297:"Todd Rider Joins Draper to Continue Antiviral Therapeutics Development"
19:
This article is about the group of antiviral drugs. For other uses, see
204:
35:
496:
195:
helices during transcription and replication. In contrast, uninfected
192:
180:
674:
188:
31:
143:
antiviral drug candidates for the treatment of alphaviruses.
70:, and was additionally found effective against influenza
199:
cells generally produce dsRNA helices of fewer than 24
675:"Dr Todd Rider's official website in regards to DRACO"
299:(Press release). Cambridge, MA. PRWeb. January 8, 2014
111:
porcine reproductive and respiratory syndrome virus
74:in weanling mice. It was reported to induce rapid
319:"PANACEA broad-spectrum antiviral therapeutics"
367:"DRACO May Be A Cure For All Viral Infections"
230:
228:
226:
224:
222:
638:"DRACOs May Be Effective Against All Viruses"
613:PANACEA broad-spectrum antiviral therapeutics
575:National Center for Biotechnology Information
97:to raise funds to test the drugs against the
8:
525:"Is a cure for the common cold on the way?"
81:As of January 2014, work had moved to
592:
582:
272:
262:
471:Journal of Applied Biotechnology Reports
563:"Broad-Spectrum Antiviral Therapeutics"
523:Hegarty, Stephanie (20 December 2011).
237:"Broad-spectrum antiviral therapeutics"
218:
699:
688:
662:
651:
425:
726:Massachusetts Institute of Technology
48:Massachusetts Institute of Technology
7:
640:. Indiegogo campaign. October 2015
46:formerly under development at the
14:
677:. Rider Institute. October 2016
610:Rider, Todd (September 2013).
1:
624:(published February 19, 2014)
545:. August 2011. Archived from
42:) is a group of experimental
584:10.1371/journal.pone.0022572
264:10.1371/journal.pone.0022572
742:
18:
483:10.30491/jabr.2020.111083
404:10.1007/s00705-015-2392-4
432:: CS1 maint: location (
16:Group of antiviral drugs
179:DRACO is selective for
54:, Amapari and Tacaribe
543:MIT Lincoln Laboratory
21:Draco (disambiguation)
113:(PRRSV) using DRACOs
721:Anti–RNA virus drugs
454:. December 15, 2015.
255:2011PLoSO...622572R
32:double-stranded RNA
698:Unknown parameter
661:Unknown parameter
323:SENS6 Proceedings
83:Draper Laboratory
52:dengue flavivirus
733:
707:
701:
696:
694:
686:
684:
682:
670:
664:
659:
657:
649:
647:
645:
633:
631:
629:
618:SENS6 Conference
606:
596:
586:
557:
555:
554:
534:
511:
510:
508:
507:
493:
487:
486:
462:
456:
455:
444:
438:
437:
431:
423:
387:
381:
380:
378:
377:
363:
357:
356:
354:
353:
339:
333:
332:
330:
329:
315:
309:
308:
306:
304:
293:
287:
286:
276:
266:
232:
741:
740:
736:
735:
734:
732:
731:
730:
711:
710:
697:
687:
680:
678:
673:
660:
650:
643:
641:
636:
627:
625:
622:SENS Foundation
609:
560:
552:
550:
537:
530:BBC News Online
522:
519:
514:
505:
503:
495:
494:
490:
464:
463:
459:
446:
445:
441:
424:
389:
388:
384:
375:
373:
365:
364:
360:
351:
349:
341:
340:
336:
327:
325:
317:
316:
312:
302:
300:
295:
294:
290:
234:
233:
220:
216:
177:
155:
87:SENS Foundation
44:antiviral drugs
24:
17:
12:
11:
5:
739:
737:
729:
728:
723:
713:
712:
709:
708:
671:
634:
607:
558:
535:
518:
517:External links
515:
513:
512:
488:
457:
439:
382:
358:
334:
310:
288:
217:
215:
212:
176:
173:
169:
168:
165:
162:
154:
151:
64:H1N1 influenza
15:
13:
10:
9:
6:
4:
3:
2:
738:
727:
724:
722:
719:
718:
716:
705:
700:|people=
692:
676:
672:
668:
663:|people=
655:
639:
635:
623:
619:
615:
614:
608:
604:
600:
595:
590:
585:
580:
576:
572:
568:
564:
559:
549:on 2013-08-23
548:
544:
540:
536:
532:
531:
526:
521:
520:
516:
502:
498:
492:
489:
484:
480:
476:
472:
468:
461:
458:
453:
449:
443:
440:
435:
429:
421:
417:
413:
409:
405:
401:
397:
393:
386:
383:
372:
368:
362:
359:
348:
344:
338:
335:
324:
320:
314:
311:
298:
292:
289:
284:
280:
275:
270:
265:
260:
256:
252:
249:(7): e22572.
248:
244:
243:
238:
231:
229:
227:
225:
223:
219:
213:
211:
208:
206:
202:
198:
194:
190:
186:
182:
174:
172:
166:
163:
160:
159:
158:
152:
150:
146:
145:
140:
137:
136:
131:
128:
126:
121:
118:
116:
112:
107:
104:
100:
96:
92:
88:
84:
79:
77:
73:
69:
65:
61:
57:
53:
49:
45:
41:
40:
37:
33:
28:
22:
679:. Retrieved
642:. Retrieved
626:. Retrieved
617:
612:
570:
566:
551:. Retrieved
547:the original
528:
504:. Retrieved
500:
491:
474:
470:
460:
452:Tech Insider
451:
442:
428:cite journal
395:
391:
385:
374:. Retrieved
370:
361:
350:. Retrieved
346:
337:
326:. Retrieved
322:
313:
301:. Retrieved
291:
246:
240:
209:
178:
170:
156:
153:Introduction
147:
141:
138:
132:
129:
124:
122:
119:
114:
108:
93:campaign at
91:crowdfunding
80:
71:
39:oligomerizer
30:
26:
25:
644:October 30,
392:Arch. Virol
205:procaspases
99:herpesvirus
715:Categories
681:October 9,
577:: e22572.
553:2012-01-02
506:2021-01-30
497:"Our Work"
376:2019-10-31
352:2015-10-26
328:2014-04-11
214:References
201:base pairs
183:-infected
103:retrovirus
68:rhinovirus
60:bunyavirus
56:arenavirus
34:activated
702:ignored (
665:ignored (
628:April 17,
501:Kimer Med
371:Indiegogo
197:mammalian
175:Mechanism
95:Indiegogo
76:apoptosis
691:cite web
654:cite web
603:21818340
567:PLOS ONE
420:16178322
412:25772577
303:April 8,
283:21818340
242:PLoS ONE
125:in vitro
115:in vitro
58:, Guama
594:3144912
274:3144912
251:Bibcode
72:in vivo
36:caspase
601:
591:
418:
410:
281:
271:
573:(7).
416:S2CID
347:PRWeb
193:dsRNA
185:cells
181:virus
27:DRACO
704:help
683:2016
667:help
646:2015
630:2014
599:PMID
434:link
408:PMID
305:2014
279:PMID
101:and
66:and
589:PMC
579:doi
479:doi
400:doi
396:160
269:PMC
259:doi
189:RNA
717::
695::
693:}}
689:{{
658::
656:}}
652:{{
620:.
616:.
597:.
587:.
569:.
565:.
541:.
527:.
499:.
473:.
469:.
450:.
430:}}
426:{{
414:.
406:.
394:.
369:.
345:.
321:.
277:.
267:.
257:.
245:.
239:.
221:^
117:.
62:,
706:)
685:.
669:)
648:.
632:.
605:.
581::
571:6
556:.
533:.
509:.
485:.
481::
475:8
436:)
422:.
402::
379:.
355:.
331:.
307:.
285:.
261::
253::
247:6
29:(
23:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.